1014 results about "Stem cell culture" patented technology

The invention relates to methods for culturing human embryonic stem cells by culturing the stem cells in an environment essentially free of mammalian fetal serum and in a stem cell culture medium including amino acids, vitamins, salts, minerals, transferring, insulin, albumin, and a fibroblast growth factor that is supplied from a source other than just a feeder layer the medium. Also disclosed are compositions capable of supporting the culture and proliferation of human embryonic stem cells without the need for feeder cells or for exposure of the medium to feeder cells.

Methods and cell culture medium for the generation of human pluripotent embryonic stem cells are disclosed. Human embryonic stem cells are cultured with human granulosa feeder cells, muscle cells, Fallopian ductal epithelial cells, bone marrow stromal cells, and skin fibroblasts and the embryonic stem cells maintain their pluripotent phenotype. The human pluripotent embryonic stem cells can be cultured without feeder cells, and in the presence of supplemental growth factors. The human pluripotent embryonic stem cells can be alternatively cultured with conditioned medium obtained from a cell culture capable of maintaining human embryonic stem cells in a pluripotent state, wherein the cell culture is a human granulosa cell culture.

The invention discloses a stem cell culture medium, an application of the stem cell culture medium and a stem cell cultivation method. Blood serum does not exist in the stem cell culture medium. The stem cell culture medium comprises amino acid, vitamin, salt, lipoid, cytokines and egg white polypeptide. The stem cell culture medium is suitable for fast cultivating stem cells which are tissue sources of human and mammal, and comprises but not is limited by fat mesenchyme stem cells, mesenchymal stem cells and umbilical cord blood stem cells. The culture medium enables increasing speed of the cells to be improved by 3-5 times, and differential potentials of the cells can not be affected. Compared with an ordinary stem cell culture medium, stem cells from different sources can be fast expanded, passage number is prolonged, and proficiency properties of the stem cells can be well kept.

While culture medium and systems have been described that permit the culture and proliferation of human embryonic stem cells in feeder free and animal product free conditions, these conditions will not readily support cloning of an embryonic stem cell culture meaning, at least here, the initiation of a sub-culture using one or a very few originating cells. It has been found here that a class of small molecules that are inhibitors of kinase enzymes will increase the efficiency of cloning of stem cell cultures sufficiently to make such cloning practical in the defined medium and in other media as well.

Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.

The invention relates to a human mesenchymal stem cell culture medium. According to the culture medium, the basal culture medium comprises the following components based on the final concentration: 1-2g/L of human serum albumin, 5-10mg/L of transferring, 2-8mg/L of fibronectin, 1-4mg/L of laminin, 50g/L of Fe(NO3)3.9H2O, 417g/L of FeSO4.7H2O, 1-3mu g/L of estradiol, 2-5mu g/L of testosterone, 1-3mu g/L of progesterone, 39.25-117.74 mu g/L of dexamethasone, 5-10mg/L of insulin, 376.36mg/L of riboflavin, 80.96-242.87mg/L of coenzyme A, 4.41-6.17mg/L of butanediamine, 1-2mg/L of taurine, 0.61-1.85mg/L of aminoethanol, 8.81-26.42mg/L of pyruvic acid, 3.78-7.56mu g/L of sodium selenate, 292.3-584.6mg/L of L-glutamine, 2-8mu g/L of vascular endothelial growth factor, 4-10mu g/L of epidermal growth factor, 4-10mu g/L of basic fibroblast growth factor, 1-5mu g/L of leukaemia inhibitory factor, 1-5mu g/L of insulin-like growth factor-I and 2-8mu g/L of stem cell factor. The culture medium does not contain the animal serum, the potential animal endogenous endotoxin or virus of the animal serum is eliminated, and the culture medium is conveniently applied to clinics.

The invention discloses preparation and application of exosome secreted by human derived blood or mesenchymal stem cell. The preparation process of exosome comprises: extracting mesenchymal stem cells from health-human body blood or a stem cell culture supernatant, performing in-vitro culture and amplification, and utilizing means such as low-temperature separation, purification and the like to prepare high-purity high-bioactivity exosome. The blood or mesenchymal stem cell secreted exosome is added into medicines, health-care products and cosmetics according to ratios for developing of products with bioactivity, is capable of effectively regulating and controlling body cell signal transduction, activating cell regeneration, enhancing health cell proliferation and differentiation capacity, further regulating physiologic restoration or removing damaged, pathologic and aged cells of a body, fundamentally changing body physiologic functions, and helping to generate anti-tumor treatment effect by adjusting cellular immunity. The blood or mesenchymal stem cell secreted exosome is applicable to fields of medical science, health care and beauty treatment, and has wide application prospect.

The invention discloses a stem cell tissue culture seedling raising technique. The technique comprises the steps of 1, taking a fresh plant, conducting sterilization on the surface and cutting the plant; 2, conducting tissue differentiation and reserving a cambium; 3, culturing the cambium on an isolation medium. According to the technique, existing methods are improved based on a traditional tissue culture technique, plant stem cells are taken as a target, induction, separation and explant culture are conducted, and a corresponding stem cell culture system is established. By the adoption of the plant stem cell culture technique, the plant culture technique is enriched, and a novel research direction and opportunity is provided for commercialized production of natural products and development of the plant biotechnology.

The invention provides a serum-free medium for umbilical cord mesenchymal stem cells and belongs to the technical field of cell culture. The serum-free medium for umbilical cord mesenchymal stem cells comprises a basal culture medium body and added ingredients, wherein the basal culture medium body is a DMEM culture medium; the added ingredients include a basic fibroblast growth factor hFGF, a epidermal growth factor hEGF, insulin hI, a leukaemia inhibitory factor hLIF and astragalus polysaccharide. The umbilical cord mesenchymal stem cells are subjected to subculture and amplification in the medium, and the surfaces of the cultured cells are marked and analyzed. The serum-free medium for umbilical cord mesenchymal stem cells overcomes the defect of exogenous pollution of serum and solves the problem of contradiction between the cell expansion number and cost reduction. The medium is free of serum, thereby preventing influence of animal-derived serum ingredients on cell culture. The medium can be used for studying the differentiation and proliferation adjusting mechanism of the umbilical cord mesenchymal stem cells.

This invention provides a microwell array having a plurality of microwells on a hydrophobic surface wherein the microwells each is substantially proximate to each of its adjacent microwells, as well as methods to prepare arrays. Also provided is a plate that comprises at least one microarray, at least one input channel, at least one output channel, and a channel connecting the input and output channel.

The present invention relates to compositions and methods for inducing the differentiation of stem cells into renal progenitor cells. In particular, the present invention provides compositions containing activin-a, retinoic acid, and bmp-7, and variants thereof, for differentiating stem cells into renal cells containing tubular epithelia. In certain embodiments, the present invention provides stem cells cultured with compositions used to treat renal disease.

The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and a cell prepared by culturing using this differentiation inhibiting agent. The present invention provides a differentiation inhibiting agent which comprises a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient; a method for safely culturing a stem cell in large scale in undifferentiated state in the absence of feeder cell which comprises culturing a stem cell by using a tetrahydroisoquinoline derivative; a culture liquid for stem cells comprising a tetrahydroisoquinoline derivative; and a cell which is obtained by culture using a tetrahydroisoquinoline derivative as a differentiation inhibiting agent.

We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.

The invention relates to a method for separating exosome from a human umbilical cord mesenchymal stem cell source and a reagent used by the method. The method comprises the following steps: (1) cultivating umbilical cord mesenchymal stem cells; and (2) extracting umbilical cord blood MSC exosome, wherein the umbilical cord mesenchymal stem cells are cultivated to P3 generation; and extraction forthe umbilical cord blood MSC exosome comprises the following steps: pre-treating exosome suspension; and extracting exosome. The reagent used by the method realtes to a solution which has a special formula and is used as a buffer pad. The method has the excellent technical effects as described in the specification.

The present invention concerns systems and methods for providing human cell cultures. Specific embodiments of the invention relate to cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.

The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.